The introduction of imatinib mesylate, an ABL tyrosine kinase inhibitor (TKI), followed by the development of second and third generation TKIs (dasatinib, nilotinib, bosutinib, and ponatinib), has dramatically improved the prognosis of patients with CML [2,3]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.